RFK Jr.’s peptide push narrowly gains backing from FDA advisers despite objections from scientists

A federal health advisory panel narrowly recommended easing FDA restrictions on peptides like BPC-157 and TB-500, despite objections from FDA scientists citing insufficient safety and efficacy data. The decision, with an 8-6 vote, could boost telehealth marketing of these substances for wellness uses, though the FDA is not obligated to follow the panel's advice.